Stomatology ›› 2022, Vol. 42 ›› Issue (7): 609-616.doi: 10.13591/j.cnki.kqyx.2022.07.007

• Clinical Research • Previous Articles     Next Articles

Microbiological and clinical effects of adjunctive azithromycin on non-surgical periodontal therapy of patients with stage Ⅲ/Ⅳ periodontitis

YANG Ruoqu, HUO Pengcheng, HU Congjiao, SHI Mingyan, LUO Lijun   

  1. Department of Periodontics, School of Stomatology, Tongji University, Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Shanghai 200072, China
  • Revised:2022-03-06 Online:2022-07-28 Published:2022-07-22

Abstract: Objective To evaluate the clinical and microbiological effects of systemic azithromycin (AZI) as an adjunct to scaling and root planing (SRP) in the treatment of stage Ⅲ/Ⅳ periodontitis. Methods Forty patients were randomized into SRP group and AZI group. Clinical examinations and saliva collection were performed at baseline, 3 days and 6 weeks after SRP. Clinical examinations analyzed the treatment effects. Salivary microbiomes were analyzed through 16S rRNA sequencing, and the differences in richness, diversity, and relative abundance of each taxon were determined. Results All the clinical parameters were significantly improved after treatment in both groups compared to baseline(P<0.001). Greater clinical attachment loss(CAL)and bleeding on probing (BOP) improvements were found in the AZI group at 3 days and 6 weeks after treatment (P<0.05); improvement in probing depth (PD)was only found at the 6th week(P<0.05). Results of site-level stratified statistics showed that periodontal indexes at the site level in the AZI group after treatment were better than those in the SRP group. All the alpha diversity indices were significantly reduced after treatment in the AZI group(P<0.05), while in SRP group, only Sobs index had a transient reduction 3 days after treatment. The proportion of Lactobacillus microbiota increased in both groups post-SRP, and was higher in the AZI group. Besides, the proportion of Treponema, and Fusobacterium decreased significantly in AZI group (P<0.05); at 3 days after treatment, the proportion of Porphyromonas decreased significantly (P<0.05), while the proportion of Prevotella increased significantly (P<0.05). However, at 6 weeks after treatment, the proportion of both regressed close to the baseline level (P>0.05). Conclusion AZI combined with non-surgical periodontal therapy, can improve clinical outcomes of severe periodontitis, change flora composition, and inhibit Treponema, Fusobacterium and Porphyromonas in periodontal red and orange pathogenic complexes.

Key words: azithromycin, scaling and root planing, periodontitis, 16S rRNA sequencing

CLC Number: